Efficacy of 3,4-diaminopyridine in the treatment of Lambert-Eaton myasthenia syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1091220208

Enrollment

Registered

2015-03-10

Start date

2017-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lambert-Eaton myasthenia syndrome

Interventions

Intervention type:DRUG Name of intervention:3,4-diaminopyridine Dose form / Japanese Medical Device Nomenclature:POWDER Route of administration / Site of application:ORAL Dose per administration:10 mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Clinically confirmed Lambert-Eaton myasthenia patients who have muscle weakness

Exclusion criteria

Exclusion criteria: Poor PS GOT,GPT>100 BUN>30,Cr>2.0

Design outcomes

Primary

Measure	Time frame
physical examinaition	—

Secondary

Measure	Time frame
Activity od daily life	—

Countries

Japan

Contacts

Public ContactHiroyuki FUKUDA

Shizuoka Cancer Center

h.fukuda@scchr.jp+81-55-989-5222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026